Serious Side Effects of Promuba
Tell your doctor immediately if you experience any of the following serious side effects:
- Numbness or tingling in the hands or feet
- White patches or sores in the mouth or on the lips
- Painful urination
- Vision problems or pain behind the eyes
- Fever or chills
- Trouble concentrating
- Mood or behavior changes
- Slurred speech
- Stiff neck
- Muscle twitching
- Joint pain
- Signs of an allergic reaction, which may include rash, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat
Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:
- numbness, pain, burning, or tingling in your hands or feet
- peeling or blistering skin
- stuffy nose, fever, sore throat, or other signs of infection
- joint pain
- difficulty speaking
- problems with coordination
Promuba may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
In elderly geriatric patients, monitoring for Promuba associated adverse events is recommended (see CLINICAL PHARMACOLOGY, PRECAUTIONS). Decreased liver function in geriatric patients can result in increased concentrations of Promuba that may necessitate adjustment of Promuba dosage (see DOSAGE AND ADMINISTRATION).
4. Tablets, liqu >
Promuba tablets, liquid and suppositories are prescribed for a number of infections, including pelvic inflammatory disease. The form your doctor prescribes, the dose and how long you'll need to take the medicine for depends on the type of infection and how serious it is.
Some infections can be treated with a single dose, while others may need a 2 week course. Children's doses are lower and depend on the age or weight of your child. Follow the instructions from your doctor or pharmacist.
Promuba tablets should be swallowed whole with a drink of water, after you've eaten some food.
Promuba liquid does not need to be taken after food. This medicine comes with a plastic syringe or spoon to help you measure out the right dose. If you don't have one, ask your pharmacist for one. Do not use a kitchen teaspoon as it will not give the right amount.
Your doctor may prescribe Promuba suppositories if you have difficulty swallowing medicines. Promuba suppositories are usually used 3 times a day. Follow the instructions that come in the packaging with your medicine.
If you need to take several doses of Promuba a day, try to space them evenly. For example, if you take your medicine 3 times a day, this could be first thing in the morning, mid-afternoon, and at bedtime.
Promuba is a prescription drug used to treat infections caused by bacteria or other parasites in different parts of your body. It works by destroying the germs that cause infection. The drug is available in several forms:
- immediate-release oral tablets and capsules
- extended-release oral tablets
- topical creams, gels, and lotions
- vaginal gels
The different forms of Promuba have different side effects. Read on to learn about the common and serious side effects that can occur with each form of Promuba.
Promuba immediate-release and extended-release tablets and capsules are taken by mouth and are absorbed through the stomach. Extended-release drugs stay active in your body for a longer period of time than immediate-release drugs do.
The extended-release tablets are used to treat vaginal infections. The immediate-release forms of Promuba are used to treat bacterial infections that affect many parts of the body as well as parasitic infections in the intestines, liver, and reproductive tract.
There are no adequate and well-controlled studies of in pregnant women; there are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used Promuba during pregnancy; many studies included first trimester exposures; one study showed increased risk of cleft lip, with or without cleft palate, in infants exposed to Promuba in utero; however, these findings were not confirmed
Promuba crosses placental barrier and its effects on human fetal organogenesis are not known; reproduction studies have been performed in rats, rabbits and mice at doses similar to maximum recommended daily dose based on body surface area comparisons; there was no evidence of harm to fetus due to Promuba; healthcare provider should carefully consider potential risks and benefits for each specific patient before prescribing therapy
- Mild to moderate renal impairment: Dose adjustment not considered necessary as elimination half-life not significantly altered
- Severe renal impairment or end stage of renal disease: Promuba and Promuba metabolites may accumulate significantly because of reduced urinary excretion; monitor in severe renal impairment or end stage of renal disease, not undergoing hemodialysis
- Hemodialysis removes significant amounts of Promuba and its metabolites from systemic circulation; supplementation may be necessary
- Peritoneal dialysis: Monitor for signs of toxicity due to potential accumulation of Promuba metabolites
Other uses for this medicine
Promuba tablets are used to treat bacterial vaginosis in women.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Hemodialysis removes significant amounts of Promuba and its metabolites from systemic circulation. The clearance of Promuba will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Promuba cannot be separated from the hemodialysis session, supplementation of Promuba dosage following the hemodialysis session should be considered, depending on the patient’s clinical situation (see CLINICAL PHARMACOLOGY).Medication: Promuba (dose and duration not given) Pattern: Hepatocellular (R=62) Severity: 3+ initially (jaundice and hospitalization) 5+ on reexposure (liver transplantation, death) Latency: